Patient case: 50-year-old female with Lung cancer. Genetic variant: EGFR (L858R). Other conditions: Lupus.

Clinical trial: Bevacizumab and Carboplatin/Paclitaxel and Radiation in Non-Small Cell Lung Cancer

Summary: This study is being done to learn what effects (good and bad) bevacizumab in conjunction with carboplatin/paclitaxel and radiation therapy has on patients with non-small cell lung cancer (NSCLC).

Detailed description: -  There are three phases of treatment 1)chemoradiation, 2) consolidation and 3)maintenance therapy.
  -  The chemoradiation phase is from week 1 to week 7. The following will occur during this phase: Daily chest radiation starting on day 1; pre-medication for paclitaxel; weekly intravenous administration of paclitaxel and carboplatin; intravenous administration of bevacizumab once weekly every three weeks starting on day 1.
  -  During weeks 8-9, patients will undergo a PET/CT scan for restaging.
  -  The consolidation phase is from week 10 to week 16. The following will occur during this phase: Pre-medication for paclitaxel; intravenous administration of paclitaxel and carboplatin twice weekly every 3 weeks; intravenous administration of bevacizumab once weekly every 3 weeks.
  -  The maintenance phase is from week 17 to week 52. The following will occur during this phase; intravenous administration of bevacizumab once a week every three weeks for 1 year; PET/CT scan every three months.
  -  The following evaluations will occur during treatment: 1)Patients will be evaluated weekly by the study doctor, 2) Weight, difficulty or discomfort in swallowing, shortness of breath and over well-being will be recorded, 3) Weekly lab test will include CBC, chemistries, and liver function tests. 4) Followed through each cycle of chemotherapy and every 6-8 weeks for the duration of the study.
  -  The following evaluations will occur after treatment: 1)Every 6-8 weeks assessed for response with a CT or PET/CT scan for one year, 2) Toxicity will also be assessed at each follow-up interval.

Eligibility: Inclusion Criteria:
  -  Histologically confirmed non-small cell lung cancer (NSCLC) that have been evaluated and determined not to be candidates for surgical resection as part of their definitive management of stage III disease.
  -  Age 18 years or older
  -  ECOG performance status of 0-1
  -  Life Expectancy of greater than six months
  -  Normal organ and marrow function
  -  Women and men of child-bearing potential must agree to use adequate contraception
  Exclusion Criteria:
  -  Prior chemotherapy or thoracic radiation therapy
  -  Squamous histology or any histology in close proximity to a major vessel
  -  Active hemoptysis
  -  History of hypercoagulability
  -  Known distant metastatic disease
  -  History of allergic reactions attributed to compounds with similar chemical or biological composition to bevacizumab, carboplatin, paclitaxel or other agents used in this study
  -  Patients with uncontrolled intercurrent illness
  -  Pregnant women
  -  Major surgical procedure, open biopsy, or significant traumatic injury with in 28 days prior to day 0
  -  Minor surgical procedure within 7 days to day 0
  -  HIV-positive patients receiving combination anti-retroviral therapy.
  -  Non-skin cancer malignancy in the past 5 years.

Relevance to patient case: not relevant